ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Endocrinology, Diabetes Metabolism

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

15,346Medicare Part D Prescriptions Filled, Including Refills

Rank: 10 out of 448

$1.66M Total Retail Price of All Prescriptions

Rank: 8 out of 448

440 Patients Receiving at Least One Drug in Part D
88%Patients 65 Years and Older
88% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in California
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

5% of this provider’s 440 patients filled at least one prescription for a schedule three drug, compared to an average of 3%.

Risky Drugs to Seniors

2% of this provider’s 14,000 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

51% of this provider’s prescriptions were for brand-name drugs, compared to an average of 45%.

Prescription Price

$108 was the average price of a prescription from this provider, compared to $111 among peers.

Prescriptions per Patient

35 is the average number of prescriptions (including refills) per patient, compared to an average of 12.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in California
METFORMIN HCL 969 861 1 2
JANUVIA 911 862 10 2 6
ACTOS 770 684 10 3 20
GLIMEPIRIDE 635 555 4 7
LOVASTATIN 633 551 5 40
SYNTHROID 529 464 6 3
LANTUS SOLOSTAR 426 375 7 10
LOSARTAN POTASSIUM 411 362 8 16
CRESTOR 326 305 9 22
HUMALOG 317 291 10 11
AMLODIPINE BESYLATE 281 273 11 12
ACTONEL 280 266 12 84
PEN NEEDLE 273 245 13 5
CARVEDILOL 255 244 14 36
DIOVAN 248 198 15 23
ATORVASTATIN CALCIUM 237 235 16 13
PIOGLITAZONE HCL 219 185 R 10 17 66
SURE COMFORT 213 199 18 78
SURE COMFORT ALCOHOL 198 176 10 19 73
NOVOLOG FLEXPEN 187 160 20 28
PRAVASTATIN SODIUM 183 159 21 31
ALCOHOL PREP PADS 168 144 22 162
BENAZEPRIL HCL 161 148 23 38
LANTUS 160 153 24 8
HYDROCHLOROTHIAZIDE 159 141 25 27
GLIPIZIDE 156 144 26 15
ONGLYZA 155 144 27 58
ATENOLOL 153 140 28 29
TAMSULOSIN HCL 148 147 29 46
WELCHOL 145 128 30 114
EVISTA 131 120 31 90
PANTOPRAZOLE SODIUM 129 117 32 62
ATELVIA 123 123 33 102
LEVEMIR FLEXPEN 115 105 34 35
HYDROCORTISONE 112 97 35 91
ZOLPIDEM TARTRATE 110 110 36 37
TRICOR 110 99 36 106
DOXAZOSIN MESYLATE 110 93 36 127
FAMOTIDINE 105 104 39 129
VIAGRA 105 105 39 198
CLOPIDOGREL 103 96 41 71
SINGLE USE SWAB 102 100 42 140
BENICAR 100 87 43 111
LEVOTHYROXINE SODIUM 100 100 43 1
PLAVIX 93 93 45 75
FUROSEMIDE 92 90 46 25
UNIFINE PENTIPS 92 85 46 163
GLUMETZA 89 68 10 48 202
ZETIA 85 85 49 41
ACTOPLUS MET 81 73 50 117
LOSARTAN-HYDROCHLOROTHIAZIDE 81 67 50 50
DEXILANT 78 78 52 98
LOVAZA 74 72 53 43
ULTRA COMFORT 74 74 53 238
AVODART 73 73 55 124
ALENDRONATE SODIUM 70 56 56 17
RAMIPRIL 68 68 57 85
LISINOPRIL 66 66 58 14
FENOFIBRATE 61 60 59 59
EXFORGE 60 60 60 105
LIPITOR 59 58 61 56
CALCITRIOL 56 44 62 54
FLUTICASONE PROPIONATE 52 52 63 88
ISOSORBIDE MONONITRATE ER 51 51 64 108
ACARBOSE 51 49 64 70
ALLOPURINOL 51 49 64 48
METOPROLOL SUCCINATE 50 43 67 39
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.